Ionis Pharmaceuticals Inc (IONS) stock
IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/303% below fair value
$27.39+0.43 (+1.59%)
Close on Nov 18, 2026Market cap $4.55BP/E –Yield –
Ionis Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ionis Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$594.36M. For fiscal 2025 it was -$381.68M. The highest annual figure on record is $365.88M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$381.68M | – |
| FY2024 | Dec 31, 2024 | -$475.08M | – |
| FY2023 | Dec 31, 2023 | -$353.73M | – |
| FY2022 | Dec 31, 2022 | -$410.19M | – |
| FY2021 | Dec 31, 2021 | -$30.19M | – |
| FY2020 | Dec 31, 2020 | -$172.08M | -147.0% |
| FY2019 | Dec 31, 2019 | $365.88M | – |
| FY2018 | Dec 31, 2018 | -$61.37M | -297.7% |
| FY2017 | Dec 31, 2017 | $31.05M | – |
| FY2016 | Dec 31, 2016 | -$20.16M | – |
| FY2015 | Dec 31, 2015 | -$75.76M | – |
| FY2014 | Dec 31, 2014 | -$47.73M | – |
| FY2013 | Dec 31, 2013 | -$51.67M | – |
| FY2012 | Dec 31, 2012 | -$68.92M | – |
| FY2011 | Dec 31, 2011 | -$71.10M | – |
| FY2010 | Dec 31, 2010 | -$48.36M | – |
| FY2009 | Dec 31, 2009 | -$27.54M | – |
| FY2008 | Dec 31, 2008 | -$13.06M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$102.29M | -173.2% |
| Q1 FY2026 | Mar 31, 2026 | -$117.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$214.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$160.18M | – |
| Q2 FY2025 | Jun 30, 2025 | $139.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$146.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$110.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$148.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$66.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$149.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$143.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$90.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$114.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$208.02M | -194.3% |
| Q3 FY2022 | Sep 30, 2022 | -$59.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$85.51M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $220.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$85.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$72.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$91.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.66M | -108.7% |
| Q3 FY2020 | Sep 30, 2020 | -$36.54M | -1548.2% |
| Q2 FY2020 | Jun 30, 2020 | -$51.75M | – |
| Q1 FY2020 | Mar 31, 2020 | -$61.13M | -150.3% |
| Q4 FY2019 | Dec 31, 2019 | $260.65M | +2317.5% |
| Q3 FY2019 | Sep 30, 2019 | $2.52M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.83M | – |
| Q1 FY2019 | Mar 31, 2019 | $121.54M | – |
| Q4 FY2018 | Dec 31, 2018 | $10.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$18.57M | -264.2% |
| Q2 FY2018 | Jun 30, 2018 | -$50.28M | -879.6% |
| Q1 FY2018 | Mar 31, 2018 | -$3.30M | -116.9% |
| Q4 FY2017 | Dec 31, 2017 | -$6.20M | -115.1% |
| Q3 FY2017 | Sep 30, 2017 | $11.31M | -29.8% |
| Q2 FY2017 | Jun 30, 2017 | $6.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $19.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $41.16M | – |
| Q3 FY2016 | Sep 30, 2016 | $16.11M | – |
See a number that looks wrong?